18F-FDG PET Imaging of Myocardial Viability in an Experienced Center with Access to 18F-FDG and Integration with Clinical Management Teams: The Ottawa-FIVE Substudy of the PARR 2 Trial

被引:108
|
作者
Abraham, Arun [1 ,2 ]
Nichol, Graham [3 ]
Williams, Kathryn A. [1 ,2 ]
Guo, Ann [1 ,2 ]
deKemp, Robert A. [1 ,2 ]
Garrard, Linda [1 ,2 ]
Davies, Ross A. [1 ,2 ]
Duchesne, Lloyd [1 ,2 ]
Haddad, Haissam [1 ,2 ]
Chow, Benjamin [1 ,2 ]
DaSilva, Jean [1 ,2 ]
Beanlands, Rob S. B. [1 ,2 ]
机构
[1] Univ Ottawa, Inst Heart, Natl Cardiac PET Ctr, Ottawa, ON K1Y 4W7, Canada
[2] Univ Ottawa, Inst Heart, Div Cardiol, Cardiovasc Res Methods Ctr, Ottawa, ON K1Y 4W7, Canada
[3] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA
关键词
cardiology (clinical); PET; fluorodeoxyglucose; LV dysfunction; viability; LEFT-VENTRICULAR DYSFUNCTION; POSITRON-EMISSION-TOMOGRAPHY; CORONARY-ARTERY-DISEASE; RANDOMIZED-TRIALS; REVASCULARIZATION; PROGNOSIS; MORTALITY; SUBGROUP; INFARCTION; SURVIVAL;
D O I
10.2967/jnumed.109.065938
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-FDG PET may assist decision making in ischemic cardiomyopathy. The PET and Recovery Following Revascularization (PARR 2) trial demonstrated a trend toward beneficial outcomes with PET-assisted management. The substudy of PARR 2 that we call Ottawa-FIVE, described here, was a post hoc analysis to determine the benefit of PET in a center with experience, ready access to F-18-FDG, and integration with clinical teams. Methods: Included were patients with left ventricular dysfunction and suspected coronary artery disease being considered for revascularization. The patients had been randomized in PARR 2 to PET-assisted management (group 1) or standard care (group 2) and had been enrolled in Ottawa after August 1, 2002 (the date that on-site F-18-FDG was initiated) (n = 111). The primary outcome was the composite endpoint of cardiac death, myocardial infarction, or cardiac rehospitalization within 1 y. Data were compared with the rest of PARR 2 (PET-assisted management [group 3] or standard care [group 4]). Results: In the Ottawa-FIVE subgroup of PARR 2, the cumulative proportion of patients experiencing the composite event was 19% (group 1), versus 41% (group 2). Multivariable Cox proportional hazards regression showed a benefit for the PET-assisted strategy (hazard ratio, 0.34; 95% confidence interval, 0.16-0.72; P = 0.005). Compared with other patients in PARR 2, Ottawa-FIVE patients had a lower ejection fraction (25% +/- 7% vs. 27% +/- 8%, P = 0.04), were more often female (24% vs. 13%, P = 0.006), tended to be older (64 +/- 10 y vs. 62 +/- 10 y, P = 0.07), and had less previous coronary artery bypass grafting (13% vs. 21%, P = 0.07). For patients in the rest of PARR 2, there was no significant difference in events between groups 3 and 4. The observed effect of F-18-FDG PET-assisted management in the 4 groups in the context of adjusted survival curves demonstrated a significant interaction (P = 0.016). Comparisons of the 2 arms in Ottawa-FIVE to the 2 arms in the rest of PARR 2 demonstrated a trend toward significance (standard care, P = 0.145; PET-assisted management, P = 0.057). Conclusion: In this post hoc group analysis, a significant reduction in cardiac events was observed in patients with F-18-FDG PET-assisted management, compared with patients who received standard care. The results suggest that outcome may be benefited using F-18-FDG PET in an experienced center with ready access to F-18-FDG and integration with imaging, heart failure, and revascularization teams.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 50 条
  • [41] Reporting Guidance for Oncologic 18F-FDG PET/CT Imaging
    Niederkohr, Ryan D.
    Greenspan, Bennett S.
    Prior, John O.
    Schoeder, Heiko
    Seltzer, Marc A.
    Zukotynski, Katherine A.
    Rohren, Eric M.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (05) : 756 - 761
  • [42] Imaging of Hepatic Ectopic Pregnancy by 18F-FDG PET/CT
    Hao, Jingwen
    Cheng, Zhen
    Hu, Na
    Xiao, Lizhi
    Wang, Yunhua
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (09) : 697 - 698
  • [43] Imaging of Acquired Demyelinating Syndrome With 18F-FDG PET/CT
    Malo-Pion, Caroline
    Lambert, Raymond
    Decarie, Jean-Claude
    Turpin, Sophie
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (02) : 103 - 105
  • [44] Clinical value of baseline 18F-FDG PET/CT in soft tissue sarcomas
    Reyes Marles, Rafael Hernando
    Navarro Fernandez, Jose Luis
    Puertas Garcia-Sandoval, Jose Pablo
    Santonja Medina, Fernando
    Mohamed Salem, Laroussi
    Frutos Esteban, Laura
    Contreras Gutierrez, Jose Fulgencio
    Castellon Sanchez, Maria Isabel
    Ruiz Merino, Guadalupe
    Claver Valderas, Maria Antonia
    EUROPEAN JOURNAL OF HYBRID IMAGING, 2021, 5 (01):
  • [45] 18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome
    Carrasquillo, Jorge A.
    Chen, Clara C.
    Price, Susan
    Whatley, Millie
    Avila, Nilo A.
    Pittaluga, Stefania
    Jaffe, Elaine S.
    Rao, V. Koneti
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (12) : 949 - 955
  • [46] Use of resting myocardial 18F-FDG imaging in the detection of unstable angina
    Dou, Ke-Fei
    Xie, Bo-Qia
    Gao, Xiao-Jin
    Li, Yan
    Yang, Yue-Jin
    He, Zuo-Xiang
    Yang, Min-Fu
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (10) : 999 - 1006
  • [47] Clinical significance of parotid gland incidentalomas on 18F-FDG PET/CT
    Makis, William
    Ciarallo, Anthony
    Gotra, Akshat
    CLINICAL IMAGING, 2015, 39 (04) : 667 - 671
  • [48] Imaging of a Case of Metaplastic Thymoma on 18F-FDG PET/CT
    Ishikawa, Yoshinori
    Kato, Katsuhiko
    Taniguchi, Tetsuo
    Kawaguchi, Koji
    Yokoi, Kohei
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (12) : E63 - E64
  • [49] Chordoma: 18F-FDG PET/CT and MRI imaging features
    Olson, Joshua T.
    Wenger, Doris E.
    Rose, Peter S.
    Petersen, Ivy A.
    Broski, Stephen M.
    SKELETAL RADIOLOGY, 2021, 50 (08) : 1657 - 1666
  • [50] Utility of 18F-FDG PET/CT in Diagnosis and Management of Mucormycosis
    Liu, Yuejian
    Wu, Hubing
    Huang, Fen
    Fan, Zhiping
    Xu, Bing
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (09) : E370 - E371